Fairmount Funds Management LLC

Investment Portfolio & 13F Holdings Analysis

About

Type: FundHoldings: 15Value: $644.6MLatest: 2025Q1

Fairmount Funds Management LLC is an institutional investment manager that filed its latest Form 13F for 2025Q1, reporting 15 holdings worth $0.6 billion. Form 13F filings provide transparency into the equity holdings of institutional investment managers with over $100 million in assets under management. This page displays the most recent portfolio holdings, allowing investors to track position changes, new investments, and portfolio composition.

AI_NATIVE detailed information: This accession holds the following tickers:[
  "KNSA",
  "NUVL",
  "AXSM",
  "BCAX",
  "ATXS",
  "SRRK",
  "SYRE",
  "APGE",
  "ZBIO",
  "IKT",
  "COGT",
  "ELVN",
  "VRDN",
  "ORKA",
  "DNTH"
]

Filing Details

13F-HR • 2025-03-31

SEC FilingSEC DataHachi Filing

Report Date: 2025-03-31
Filing Date: 2025-05-15
Total Holdings: 15
Total Value: 644620652
Accession Number: 0001104659-25-049337
Form Type: 13F-HR
CIK: fairmount-funds-management
Manager Name: Fairmount-Funds-Management

Data Enrichment

100% identified

15 identified0 unidentified

Holdings

SEC FilingSEC DataHachi Filing

Manager:

15 positions • $644.6M total value

SEC FilingSEC DataHachi Filing

Manager:

Search and click to pin securities to the top

Sort by:

Axsome Therapeutics, Inc.

AXSM|05464T104

Shares:815.2K

Value:$95.1M

% of Portfolio:14.7% ($95.1M/$644.6M)

Apogee Therapeutics, Inc.

APGE|03770N101

Shares:2.0M

Value:$76.5M

% of Portfolio:11.9% ($76.5M/$644.6M)

Spyre Therapeutics, Inc.

SYRE|00773J202

Shares:4.0M

Value:$64.8M

% of Portfolio:10.1% ($64.8M/$644.6M)

Enliven Therapeutics, Inc.

ELVN|29337E102

Shares:3.2M

Value:$63.0M

% of Portfolio:9.8% ($63.0M/$644.6M)

Nuvalent, Inc.

NUVL|670703107

Shares:727.6K

Value:$51.6M

% of Portfolio:8.0% ($51.6M/$644.6M)

Dianthus Therapeutics, Inc. /DE/

DNTH|252828108

Shares:2.7M

Value:$49.0M

% of Portfolio:7.6% ($49.0M/$644.6M)

Viridian Therapeutics, Inc.\DE

VRDN|92790C104

Shares:3.4M

Value:$46.4M

% of Portfolio:7.2% ($46.4M/$644.6M)

Scholar Rock Holding Corp

SRRK|80706P103

Shares:1.4M

Value:$44.2M

% of Portfolio:6.9% ($44.2M/$644.6M)

Cogent Biosciences, Inc.

COGT|19240Q201

Shares:6.2M

Value:$37.3M

% of Portfolio:5.8% ($37.3M/$644.6M)

Oruka Therapeutics, Inc.

ORKA|687604108

Shares:3.4M

Value:$34.6M

% of Portfolio:5.4% ($34.6M/$644.6M)

Kiniksa Pharmaceuticals International, plc

KNSA|G52694109

Shares:1.1M

Value:$24.5M

% of Portfolio:3.8% ($24.5M/$644.6M)

Astria Therapeutics, Inc.

ATXS|04635X102

Shares:3.6M

Value:$19.0M

% of Portfolio:2.9% ($19.0M/$644.6M)

Zenas BioPharma, Inc.

ZBIO|98937L105

Shares:1.9M

Value:$15.0M

% of Portfolio:2.3% ($15.0M/$644.6M)

Inhibikase Therapeutics, Inc.

IKT|45719W205

Shares:6.1M

Value:$13.4M

% of Portfolio:2.1% ($13.4M/$644.6M)

Bicara Therapeutics Inc.

BCAX|055477103

Shares:784.2K

Value:$10.2M

% of Portfolio:1.6% ($10.2M/$644.6M)

Instrument	Shares		Other Manager	Value	% of Portfolio
Axsome Therapeutics, Inc.(AXSMcusip05464T104)	815.2K	QoQ -44.50% (-653.8K) YoY -65.45% (-1.5M)	All Managers (Combined)	$95.1M	14.7% ($95.1M/$644.6M)	QoQ -23.50% (-$29.2M) YoY -49.51% (-$93.3M)
Apogee Therapeutics, Inc.(APGEcusip03770N101)	2.0M	QoQ 0.00% (-0) YoY 0.00% (-0)	All Managers (Combined)	$76.5M	11.9% ($76.5M/$644.6M)	QoQ -17.52% (-$16.3M) YoY -43.77% (-$59.6M)
Spyre Therapeutics, Inc.(SYREcusip00773J202)	4.0M	QoQ 0.00% (-0) YoY +961.80% (+3.6M)	All Managers (Combined)	$64.8M	10.1% ($64.8M/$644.6M)	QoQ -30.69% (-$28.7M) YoY +351.68% (+$50.5M)
Enliven Therapeutics, Inc.(ELVNcusip29337E102)	3.2M	QoQ 0.00% (-0) YoY 0.00% (+0)	All Managers (Combined)	$63.0M	9.8% ($63.0M/$644.6M)	QoQ -12.53% (-$9.0M) YoY +11.88% (+$6.7M)
Nuvalent, Inc.(NUVLcusip670703107)	727.6K	QoQ -44.78% (-590.1K) YoY -62.19% (-1.2M)	All Managers (Combined)	$51.6M	8.0% ($51.6M/$644.6M)	QoQ -49.97% (-$51.5M) YoY -64.29% (-$92.9M)
Dianthus Therapeutics, Inc. /DE/(DNTHcusip252828108)	2.7M	QoQ 0.00% (-0) YoY -2.24% (-62.1K)	All Managers (Combined)	$49.0M	7.6% ($49.0M/$644.6M)	QoQ -16.78% (-$9.9M) YoY -40.89% (-$33.9M)
Viridian Therapeutics, Inc.\DE(VRDNcusip92790C104)	3.4M	QoQ 0.00% (-0) YoY +86.68% (+1.6M)	All Managers (Combined)	$46.4M	7.2% ($46.4M/$644.6M)	QoQ -29.68% (-$19.6M) YoY +43.71% (+$14.1M)
Scholar Rock Holding Corp(SRRKcusip80706P103)	1.4M	QoQ -30.00% (-588.9K) YoY NEW(+1.4M)	All Managers (Combined)	$44.2M	6.9% ($44.2M/$644.6M)	QoQ -47.93% (-$40.7M) YoY NEW(+$44.2M)
Cogent Biosciences, Inc.(COGTcusip19240Q201)	6.2M	QoQ 0.00% (-0) YoY +31.74% (+1.5M)	All Managers (Combined)	$37.3M	5.8% ($37.3M/$644.6M)	QoQ -23.20% (-$11.3M) YoY +17.43% (+$5.5M)
Oruka Therapeutics, Inc.(ORKAcusip687604108)	3.4M	QoQ 0.00% (-0) YoY NEW(+3.4M)	All Managers (Combined)	$34.6M	5.4% ($34.6M/$644.6M)	QoQ -47.08% (-$30.8M) YoY NEW(+$34.6M)
Kiniksa Pharmaceuticals International, plc(KNSAcusipG52694109)	1.1M	QoQ -49.76% (-1.1M) YoY NEW(+1.1M)	All Managers (Combined)	$24.5M	3.8% ($24.5M/$644.6M)	QoQ -43.59% (-$18.9M) YoY NEW(+$24.5M)
Astria Therapeutics, Inc.(ATXScusip04635X102)	3.6M	QoQ 0.00% (-0) YoY 0.00% (-0)	All Managers (Combined)	$19.0M	2.9% ($19.0M/$644.6M)	QoQ -40.26% (-$12.8M) YoY -62.06% (-$31.0M)
Zenas BioPharma, Inc.(ZBIOcusip98937L105)	1.9M	QoQ 0.00% (-0) YoY NEW(+1.9M)	All Managers (Combined)	$15.0M	2.3% ($15.0M/$644.6M)	QoQ -3.54% (-$548.9K) YoY NEW(+$15.0M)
Inhibikase Therapeutics, Inc.(IKTcusip45719W205)	6.1M	QoQ 0.00% (-0) YoY NEW(+6.1M)	All Managers (Combined)	$13.4M	2.1% ($13.4M/$644.6M)	QoQ -32.61% (-$6.5M) YoY NEW(+$13.4M)
Bicara Therapeutics Inc.(BCAXcusip055477103)	784.2K	QoQ -38.93% (-500.0K) YoY NEW(+784.2K)	All Managers (Combined)	$10.2M	1.6% ($10.2M/$644.6M)	QoQ -54.32% (-$12.2M) YoY NEW(+$10.2M)